PCT/EP 03/11024

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C12N5/08					
	o international Patent Classification (IPC) or to both national classific SEARCHED	cation and IPC			
Minimum de	ocumentation searched (classification system followed by classificat	lon symbols)			
IPC 7	C12N C12M				
Documenta	ion searched other than minimum documentation to the extent that	such decuments are included in the fields on	arched		
Documenta	ion seather other main minimum documentation to the extent that :	such documents are included in the helds se	arched		
Electronic d	ata base consulted during the International search (name of data ba	ase and, where practical, search terms used)		
EPO-Internal, WPI Data, BIOSIS, MEDLINE					
	ENTS CONSIDERED TO BE RELEVANT	· · · · · · · · · · · · · · · · · · ·			
Category °	Citation of document, with indication, where appropriate, of the re-	levant passages	Relevant to claim No.		
X	CESANO A ET AL: "Phase I clinic		1-7,		
	with a human major histocompatib		11–16		
	complex nonrestricted cytotoxic T-cell line (TALL-104) in dogs with advanced				
	tumors"				
	CANCER RESEARCH, vol. 56, no. 13, 1 July 1996 (199	26_07_01)			
	pages 3021-3029, XP001019009	90 07 017,	İ		
	ISSN: 0008-5472				
	cited in the application page 3022, "Large-scale expansion	n of			
	TALL-104 cells for therapy"	. •			
		-/			
		-/			
X Furth	X Further documents are listed in the continuation of box C. Patent family members are listed in annex.				
° Special car	egories of cited documents :	*T* later document published after the inter			
A document defining the general state of the art which is not considered to be of particular relevance or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention					
filing d	E* earlier document but published on or after the International "X" document of particular relevance; the claimed invention				
which i	cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone which is cited to establish the publication date of another				
O docume	or other special reason (as specified) referring to an oral disclosure, use, exhibition or	cannot be considered to involve an inv document is combined with one or more	entive step when the e other such docu~		
other means "P" document published prior to the international filing date but		ments, such combination being obvious in the art.	•		
later than the priority date claimed Date of the actual completion of the international search		&" document member of the same patent family Date of mailing of the international search report			
1	March 2004	09/03/2004			
Name and mailing address of the ISA		Authorized officer			
	European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk				
	Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Teyssier, B			



	\
Internationa	cation No
PCT/EP	03/11024

			3/11024		
C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT					
Category *	Citation of document, with indication, where appropriate, of the relevant passages		Relevant to claim No.		
X	VISONNEAU S ET AL: "Successful treatment of canine malignant histocytosis with the human major histocompatibility complex nonrestricted cytotoxic T-cell line TALL-104." CLINICAL CANCER RESEARCH, vol. 3, no. 10, October 1997 (1997-10), pages 1789-1797, XP002236334 ISSN: 1078-0432 cited in the application page 1790, "Large-scale expansion of TALL-104 cells for therapy"		1-7, 11-16		
A	TUYAERTS S ET AL: "Generation of large numbers of dendritic cells in a closed system using Cell Factories." JOURNAL OF IMMUNOLOGICAL METHODS, vol. 264, no. 1-2, 1 June 2002 (2002-06-01), pages 135-151, XP004362076 ISSN: 0022-1759		·		
Ρ,Α	BERGER T G ET AL: "Large-scale generation of mature monocyte-derived dendritic cells for clinical application in cell factories." JOURNAL OF IMMUNOLOGICAL METHODS, vol. 268, no. 2, 15 October 2002 (2002-10-15), pages 131-140, XP004379143 ISSN: 0022-1759				